A

Rating buyAI MemoPost-earnings T+3

Agilent

As of 2026-08-31/Post-earnings T+3/Confidence high/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-31 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

high

Horizon

6‑12m

Key catalyst

Q3 FY2026 beat and raised full-year outlook • 2026-08-26

Base target: $176 / p=55% prob

Biggest risk

The initial after-hours reaction was positive, but the RankAlpha anchor price of $153.84 remained below the reported $160 after-hours level. Margin and EPS guidance also include tariff-refund benefits, while demand recovery and Biocare integration still require execution. Analyst target changes are secondary evidence and the packet's own analyst-count field remains unavailable.

Invalidation

Break below $140 or thesis failure.

What would change my mind?

The Q3 beat, raised FY2026 outlook, broad-based demand, product traction, and margin expansion materially improve the operating backdrop. A secondary Benzinga page lists 18 analysts, with 16 Buy and 2 Hold ratings, and multiple August 27 target increases, including Stifel from $170 to $180 and JPMorgan from $180 to $190: https://www.benzinga.com/quote/A/price-targets

Research note

Recommendation

buy

Confidence

high

As of

2026-08-31

Base target

$176

p=55%

Bull target

$190

p=25%

Bear target

$140

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-print market reaction and analyst target revisions
Biocare acquisition closing and integration
Operating leverage and product-cycle execution

BearKey bullets

Biocare closing, regulatory approvals, and integration could delay expected growth and mix benefits [#PR-2026-03-09].
China and end-market recovery may prove uneven despite the current improvement.
Future tariff-refund benefits are excluded from Q4 guidance, and a reversal or worsening trade environment could pressure margins [#SEC-8K-2026-08-26].

WatchKey bullets

Q3 FY2026 beat and raised full-year outlook

Summary

High-level snapshot

Recommendation

buy

Model confidence

high

Timeframe

6‑12m

Asset

Equity

Trigger

Post-earnings T+3

Base case: $176 (p=55%)

Target spread vs base: +8% / -20%

Scenario probabilities

Bull Target: $190 (p=25%)Base Target: $176 (p=55%)Bear Target: $140 (p=20%)

Commentary

The company-source gap is closed by Agilent's detailed Q3 investor-relations release and corresponding SEC 8-K [#SEC-8K-2026-08-26]. News and analyst tone are constructive: Reuters-republished coverage reported a 3.17% after-hours rise, and secondary analyst data showed broad August 27 target increases. However, the $153.84 RankAlpha anchor was below the reported $160 after-hours level, and analyst data are secondary and inconsistent with the packet's missing count field. Conviction remains positive but should stay monitoring-oriented.

As of 2026-08-31 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-print market reaction and analyst target revisions
Biocare acquisition closing and integration
Operating leverage and product-cycle execution

Scenarios

Bull Target (Scenario probability)

$190 / p=25% prob

Base Target (Scenario probability)

$176 / p=55% prob

Bear Target (Scenario probability)

$140 / p=20% prob

Analysis 2026-08-31 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-08-26
Q3 FY2026 beat and raised full-year outlook
Agilent reported Q3 revenue of $1.88 billion, 7.3% core growth, 28.3% non-GAAP operating margin, and $1.62 non-GAAP EPS, while raising FY2026 revenue, margin, and EPS guidance. The company also cited improving end markets, stronger regional demand, and customer response to new product launches. Primary confirmation: [#SEC-8K-2026-08-26]. Official release: https://www.investor.agilent.com/news-and-events/news/news-details/2026/Agilent-Reports-Third-Quarter-Fiscal-Year-2026-Financial-Results/default.aspx
Prob 100.00% • Move 4.00% • Priced-in 85.00%

Short-term Catalysts

Next few weeks

Post-print market reaction and analyst target revisions
2026-08-27
Reuters-republished coverage reported a 3.17% after-hours rise to $160 from a $155.08 regular-session close. A Benzinga analyst page subsequently listed multiple August 27 target increases, including Stifel $170 to $180, JPMorgan $180 to $190, and RBC $155 to $185. These are secondary confirmation, not independent operating evidence. Sources: https://www.investing.com/news/transcripts/earnings-call-transcript-agilent-tops-q3-2026-estimates-lifts-outlook-93CH-4878009 and https://www.benzinga.com/quote/A/price-targets
Prob 100% • Move 3% • Priced-in 100%

Long-term Catalysts

Months to a year

Biocare acquisition closing and integration
2026-10-31
The planned $950 million Biocare Medical acquisition remains a tangible pathology and non-instrument mix lever, with closing targeted by fiscal Q4 2026 and expected longer-term accretion if approvals and integration remain on track [#PR-2026-03-09].
Prob 60% • Move 5% • Priced-in 40%
Operating leverage and product-cycle execution
2026-10-31
Improving end markets, customer response to new product launches, China momentum, pricing, and the Ignite Operating System support continued margin expansion and FY2026 guidance conversion [#SEC-8K-2026-08-26].
Prob 70% • Move 6% • Priced-in 60%

Risks

Biocare closing, regulatory approvals, and integration could delay expected growth and mix benefits [#PR-2026-03-09].
China and end-market recovery may prove uneven despite the current improvement.
Future tariff-refund benefits are excluded from Q4 guidance, and a reversal or worsening trade environment could pressure margins [#SEC-8K-2026-08-26].
The initial post-earnings price gain was not fully retained relative to the reported $160 after-hours level, indicating elevated expectations or profit-taking.
The packet lacks a usable analyst-count field and social coverage, limiting independent sentiment confirmation.

Peers

Symbol	Summary
WAT	Direct analytical-instruments and lab-workflow comparator for chromatography, replacement cycles, and service attachment [#10-K-2025-12-22].
TMO	Large life-science tools and services benchmark, useful for broader end-market demand and mix comparison [#10-K-2025-12-22].
DHR	Broad diagnostics and instruments benchmark for pathology and workflow execution [#10-K-2025-12-22].
BRKR	Focused analytical-instruments peer for testing whether replacement-cycle demand is broad-based [#10-K-2025-12-22].

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-31

Loading AI feed…

Symbol

Summary

WAT

Direct analytical-instruments and lab-workflow comparator for chromatography, replacement cycles, and service attachment [#10-K-2025-12-22].

TMO

Large life-science tools and services benchmark, useful for broader end-market demand and mix comparison [#10-K-2025-12-22].

DHR

Broad diagnostics and instruments benchmark for pathology and workflow execution [#10-K-2025-12-22].

BRKR

Focused analytical-instruments peer for testing whether replacement-cycle demand is broad-based [#10-K-2025-12-22].